



CIN No. : L24230TG1995PLC020093

# CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

To,

Date: 02.06.2023

BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai-400 001  
Dear Sir/Madam,

**Sub: Publication of Audited financial results for quarter and year ended 31.03.2023**

**Ref: Scrip Code: 538965**

With reference to the Regulation 47(1)(b) read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed newspaper clippings published in Financial Express and Nava Telangana on 01.06.2023, in respect of Audited financial results (Standalone & Consolidated) for quarter and year ended 31.03.2023.

Thanking you.

Yours Faithfully,  
For Concord Drugs Limited

*S. Nagi Reddy*

S. Nagi Reddy  
Chairman & Managing Director  
DIN: 01764665



Encl: as above



**CONCORD DRUGS LIMITED**

CIN: L24230TG1995PLC020093

Survey No.249, Brahmanpally Village, Hayathnagar Mandal, R.R. Dist, Hyderabad, Telangana, 501511

**AN EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MAR, 2023**  
(All amounts are in Rs.Lakhs, unless otherwise stated)

PARTICULARS	Standalone			Consolidated		
	Quarter Ended 31-03-2023 Audited	Year Ended 31-03-2023 Audited	Quarter Ended 31-03-2022 Audited	Quarter Ended 31-03-2022 Audited	Year Ended 31-03-2023 Audited	Year Ended 31-03-2022 Audited
1 Total income from operations	1154.08	5132.31	5905.73	1230.71	5208.94	5905.73
2 Net Profit/ loss (before Tax, Exceptional and/or Extraordinary items)	1.74	112.56	224.81	14.07	124.89	224.81
3 Net Profit/ loss before tax (after Exceptional and/or Extraordinary items)	1.74	112.56	224.81	14.07	124.89	224.81
4 Net Profit/ loss after tax (after Exceptional and/or Extraordinary items)	6.94	89.22	159.43	16.27	98.55	159.43
5 Total Comprehensive Income [Comprising Profit/ loss after tax and Other Comprehensive Income (after tax)]	6.94	89.22	159.43	16.27	98.55	159.43
6 Paid up Equity Share Capital (Rs.10/- Per Equity Share)	931.55	931.55	874.38	931.55	931.55	874.38
7 Earnings Per Share (of Rs.10/- each) (Not Annualised):						
a) Basic	0.07	0.96	1.82	0.17	1.06	1.82
b) Diluted	0.07	0.96	1.82	0.17	1.06	1.82

**Notes**  
1. The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30.05.2023.  
2. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Audited Financial Results are available on Company's website at www.concorddrugs.in and the stock exchange's website at www.bseindia.com.

Place : Hyderabad Date : 31-05-2023  
S.Nagi Reddy  
Chairman & Managing Director  
DIN: 01764665

**BANKA BIOLOO LIMITED**

R/o: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

C/o: Prestige Phoenix, 5 th floor, 1405, Uma Nagar, Begumpet, Hyderabad - 500016  
+91 7780301502 +info@bankabio.com +www.bankabio.com + CIN: L90001TG2012PLC082811

**Extract of audited Financial Results (both standalone and consolidated) for the quarter and year ended 31.03.2023** (RS. IN LAKS)

PARTICULARS	Standalone			Consolidated		
	Quarter Ended 31-03-2023 Audited	Year Ended 31-03-2023 Audited	Year Ended 31-03-2022 Audited	Quarter Ended 31-03-2023 Audited	Year Ended 31-03-2023 Audited	Year Ended 31-03-2022 Audited
Total income	1241.19	4295.56	3908.75	853.16	4305.09	3920.45
Net Profit (before Tax, Exceptional and/or Extra-ordinary items)	100.05	414.78	326.00	59.32	362.41	330.89
Net Profit before tax (after Exceptional and/or Extra-ordinary items)	100.05	414.78	326.00	59.32	362.41	330.89
Net Profit after tax (after Exceptional and/or Extra-ordinary items)	43.54	307.64	305.87	1.45	253.89	310.76
Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	49.35	313.44	309.27	7.25	259.70	314.17
Paid up Equity Share Capital (Rs.10 per Equity Share)	1084.66	1084.66	1084.66	1084.66	1084.66	1084.66
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet	2974.28	2974.26	2660.84	2925.24	2925.24	2665.53
Earnings Per Share (Not Annualised for quarter)						
a) Basic	0.40	2.84	2.97	0.07	2.39	3.02
b) Diluted	0.40	2.84	2.97	0.07	2.39	3.02

**Note**  
1) The above standalone and consolidated financial results are reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30 May 2023.  
2) The above is an extract of the detailed format of Financial Results filed with National Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on company's website at www.bankabio.com and the stock exchange's website, www.nseindia.com

For Banka BioLoo Limited  
Sd/-  
Namita Sanjay Banka  
Managing Director  
DIN: 05017358  
Place : Hyderabad  
Date : 31-05-2023

**RICH 'N' RICH FINANCE AND HOLDINGS LIMITED**

CIN:L65910TG1992PLC014708

Registered Office: Flat No.403, Nirmal towers, Dwarakapuri Colony,Punjagutta Hyderabad Telangana,500082,India.

**Extract of Audited Standalone financial results for the fourth Quarter and year ended 31.03.2023** (RS. IN LAKHS)

Sr. No.	PARTICULARS	Quarter ended 31-03-2023 Audited	Quarter ended 31-03-2022 Audited	Year ended 31-03-2023 Audited	Year ended 31-03-2022 Audited
		1 Total Income	170.67	176.41	560.88
2 Net Profit (before Tax, Exceptional and/or Extraordinary items)	61.93	101.28	173.34	145.27	
3 Net Profit before tax (after Exceptional and/or Extraordinary items)	61.93	101.28	173.34	145.27	
4 Net Profit after tax (after Exceptional and/or Extraordinary items)	45.74	71.56	129.11	104.47	
5 Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	45.74	71.56	129.11	104.47	
6 Paid up Equity Share Capital (Rs. 10/- Per Equity Share)	500.00	500.00	500.00	500.00	
7 Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year ended)	-	-	281.15	152.05	
8 Earnings Per Share (of Rs. 10/- each) (Not Annualised):					
a) Basic	0.91	1.43	2.58	2.09	
b) Diluted	0.91	1.43	2.58	2.09	

**Note:**  
1) The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at its meeting held on 30th May 2023.  
2) The Financial Results include the results for the Quarter Ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current Financial Year which are subject to limited review by the statutory auditors of the company.  
3) The above is an extract of the detailed format of Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on company's website at http://www.rnrlimited.com/ and the stock exchange's website i.e.https://www.mse.in/.

By and on behalf of the Board of Directors of Rich 'N' Rich Finance and Holdings Limited  
Sd/-  
Lakshmi Satyarsi Nekkanti  
Chairperson  
DIN: 07223878  
Place : Hyderabad  
Date : 30-05-2023

**VARIMAN GLOBAL ENTERPRISES LIMITED**

1-4-879/62 Gandhinagar Bank Colony, Hyderabad - 500020Telangana, India.

CIN: L67120TG1993PLC016767 Website : www.varimanglobal.com

**An Extract of Consolidated Audited Financial Results for the Quarter and Year ended 31st March, 2023** (Rs. in Lakhs)

Sr. No.	PARTICULARS	STANDALONE			CONSOLIDATED		
		QUARTER ENDED 31-03-2023 Audited	YEAR ENDED 31-03-2023 Audited	Quarter ENDED 31-03-2022 Audited	QUARTER ENDED 31-03-2023 Audited	YEAR ENDED 31-03-2023 Audited	Quarter ENDED 31-03-2022 Audited
1 Total income from operations		1113.66	5124.03	2292.55	2754.27	11605.82	7670.56
2 Net Profit/ loss (before Tax, Exceptional and/or Extraordinary items)		2.19	159.52	8.41	24.56	230.18	64.16
3 Net Profit/ loss before tax (after Exceptional and/or Extraordinary items)		2.19	159.52	8.41	24.56	230.18	64.16
4 Net Profit/ loss after tax (after Exceptional and/or Extraordinary items)		2.52	127.62	5.76	28.59	187.26	51.27
5 Total Comprehensive Income [Comprising Profit/ loss after tax and Other Comprehensive Income (after tax)]		2.52	127.62	5.76	28.59	187.26	51.27
6 Paid up Equity Share Capital (Rs.10/- Per Equity Share)		1980.11	1980.11	1799.25	1980.11	1980.11	1799.25
7 Earnings Per Share (of Rs.10/- each) (Not Annualised):							
a) Basic		0.00	0.06	0.00	0.01	0.09	0.31
b) Diluted		0.00	0.06	0.00	0.01	0.09	0.31

**Note:**  
1. The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30.05.2023.  
2. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Audited Financial Results are available on Company's website at www.varimanglobal.com and the stock exchange's website at www.bseindia.com.

For Variman Global Enterprises Limited  
Sd/-  
D. Sirish  
Managing Director  
DIN : 0199844  
Place : Hyderabad  
Date : 31-05-2023

**SAMPRE NUTRITIONS LIMITED**  
CIN No.: L15499TG1991PLC013515  
Regd Office: Plot No. 133, Industrial Estate, Medchal - 501401, Telangana. www.sampretd.com Email: gurbani@gurbani.in

**EXTRACT OF AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FINANCIAL YEAR ENDED 31st MARCH, 2023** (₹ in lakhs)

Sr. No.	Particulars	Quarter Ended (Audited)	Year Ended (Audited)
		31.03.2023	31.03.2022
1. Total income from operations (net)		1172.79	738.90
2. Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)		(49.99)	(44.46)
3. Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)		(49.99)	(44.46)
4. Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)		(55.77)	(16.83)
5. Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]		(55.77)	(16.83)
6. Equity Share Capital		687.00	482.00
7. Other Equity		-	1426.75
8. Earnings Per Share (of ₹ 10/- each)			
a) Basic		(0.97)	(0.35)
b) Diluted		(0.59)	(0.35)

**NOTES:**  
1. The above is an extract of the detailed format of Financial Results for the quarter and financial year ended 31st March, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited quarterly and financial year ended results are available on the website of the Stock Exchange. (www.bseindia.com).  
2. There are no Exceptional and Extraordinary items during the quarter.

For Sampre Nutritions Limited  
Sd/-  
B. K. GURBANI  
Managing Director  
Date: 30.05.2023  
Place: Medchal

**GROWTH IN TURNOVER @ 58.86%**  
**PROFIT AFTER TAX @ 12.69%**

**ATHENA GLOBAL TECHNOLOGIES LIMITED**

3rd Floor, Western Wing, NCC House, Survey No. 64, Madhapur, Hyderabad - 500 082.

**EXTRACTS OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2023** (Rs. in Lakhs)

PARTICULARS	STANDALONE			CONSOLIDATED		
	Quarter Ended 31.03.2023 (Audited)	Year Ended 31.03.2023 (Audited)	Quarter Ended 31.12.2022 (Audited)	Quarter Ended 31.03.2023 (Audited)	Year Ended 31.03.2023 (Audited)	Quarter Ended 31.12.2022 (Audited)
Total income from operations (net)	207.68	1,154.67	392.46	212.15	1,259.79	569.94
Net Profit / (Loss) for the period (before tax, exceptional and/or Extraordinary items)	(386.16)	(956.25)	(116.41)	(798.67)	(2,265.11)	(329.72)
Net Profit / (Loss) for the period before tax (after exceptional and/or Extraordinary items)	(386.16)	(956.25)	(116.41)	(798.67)	(2,265.11)	(329.72)
Net Profit / (Loss) for the period after tax (after exceptional and/or Extraordinary items)	(332.75)	(890.15)	(65.18)	(749.82)	(2,202.52)	(283.23)
Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	(321.81)	(839.90)	(51.69)	(741.98)	(2,155.38)	(269.74)
Equity Share Capital	1,338.00	1,338.00	1,275.00	1,338.00	1,338.00	1,275.00
Reserves (excluding Revaluation Reserve as shown in the balance sheet of previous year)		(517.85)			(2,693.67)	
Earnings per share (before extraordinary items) (of Rs. 10/- each)						
(a) Basic	(2.49)	(6.65)	(0.51)	(5.60)	(16.46)	(2.22)
(b) Diluted	(2.49)	(6.65)	(0.51)	(5.60)	(16.46)	(2.22)
Earnings per share (after extraordinary items) (of Rs.10/- each)						
(a) Basic	(2.49)	(6.65)	(0.51)	(5.60)	(16.46)	(2.22)
(b) Diluted	(2.49)	(6.65)	(0.51)	(5.60)	(16.46)	(2.22)

**Notes:**  
1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th May 2023.  
2. The above is an extract of the detailed format of Quarterly /Annual Financial Results filed with the Stock Exchanges under regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the Stock Exchange website. i.e. BSE Limited at www.bseindia.com

For Athena Global Technologies Limited  
Sd/-  
M SATYENDRA  
MANAGING DIRECTOR  
Date: 30.05.2023  
Place: Hyderabad

**indianexpress.com**

**I look at every side before taking a side.**

**Inform your opinion with insightful perspectives.**

**The Indian Express. For the Indian Intelligent.**

**The Indian EXPRESS**  
— JOURNALISM OF COURAGE —

**BARTRONICS INDIA LIMITED**

Regd. Office: Survey No. 351, Raj Bollaram Village, Medchal Mandal and District - 501401, Telangana. Email ID:info@bartronics.com|

Contact No.: 040 4926 9269, Website: www.bartronics.com, CIN: L29309TG1990PLC011721,

**STATEMENT OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023** (Rs. In Lakhs)

Sl. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended 31-03-2023 (Audited)	Quarter Ended 31-12-2022 (Unaudited)	Quarter Ended 31-03-2022 (Audited)	Year Ended 31-03-2023 (Audited)	Year Ended 31-03-2022 (Audited)	Quarter Ended 31-03-2023 (Audited)	Quarter Ended 31-12-2022 (Unaudited)	Quarter Ended 31-03-2022 (Audited)	Year Ended 31-03-2023 (Audited)	Year Ended 31-03-2022 (Audited)
1 Revenue from Operations		1,205.41	1,147.37	1,822.82	5,262.71	6,556.18	1,205.41	1,147.37	1,822.82	5,262.71	6,556.18
2 Net Profit / (Loss) for the period (before Tax and Exceptional items#)		(76.95)	(116.14)	(1,230.64)	(2,783.14)	(5,088.18)	(76.95)	(116.14)	(1,230.64)	(2,783.14)	(5,088.18)
3 Net Profit / (Loss) for the period before tax (after Exceptional items#)		15,675.24	(116.14)	(1,230.64)	12,969.05	(5,088.18)	45,893.23	(116.14)	(1,230.64)	43,187.04	(5,088.18)
4 Net Profit / (Loss) for the period after tax (after Exceptional items#)		13,770.14	(100.36)	(1,215.96)	11,022.44	(5,030.12)	43,988.13	(100.36)	(1,215.96)	41,240.43	(5,030.12)
5 Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]		10,081.67	508.37	(586.19)	11,022.44	(3,848.37)	43,988.13	508.37	(586.19)	41,240.43	(3,848.37)
6 Equity Share Capital		3,045.77	304.58	3,404.89	3,045.77	3,404.89	3,045.77	304.58	3,404.89	3,045.77	3,404.89
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year		(504.98)	(14,656.48)	(14,656.48)	(504.98)	(14,656.48)	49,777.29	3,241.98	3,241.98	49,777.29	3,241.98
8 Earnings per equity share (Face value of Re.1/- Each from 04.11.2022*)											
- Basic (Rs.)		4.52	(0.33)	(3.57)	3.62	(14.77)	14.44	(0.33)	(3.57)	13.54	(14.77)
- Diluted (Rs.)		4.52	(0.33)	(3.57)	3.62	(14.77)	14.44	(0.33)	(3.57)	13.54	(14.77)

**NOTES:** The above is an extract of the detailed format of audited financial results filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. The full format of audited financial results are available on the website of stock exchange (www.bseindia.com & www.nseindia.com) and on companies website www.bartronics.com.

Place : Hyderabad Date : 30-05-2023  
Venu Gopal Thota  
Managing Director  
DIN:01979738

**RAVILEELA GRANITES LIMITED**

Address: H. No. 6-3-668/10/35, Durganagar Colony, Punjagutta, Hyderabad - 500082

CIN # L14102AP1990PLC011909 Website: www.ravileelagrantes.co

**EXTRACTS OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023** (Rs in Lakhs)

Sr. No.	PARTICULARS	3 Months Ended 31-03-2023 Audited	3 Months Ended 31-03-2022 Audited	Year Ended 31-03-2023 Audited	Year Ended 31-03-2022 Audited
		1 Total Income from Operations and Other Income	825.22	415.24	3114.05
2 Net Profit/(Loss) for the period (Before Tax, Exceptional and / or Extraordinary items #)	(153.30)	(399.59)	40.72	139.78	
3 Net Profit/(Loss) for the period before tax (after Exceptional and / or Extraordinary items #)	(153.30)	(399.59)			



మణిపూర్లో ఆదివాసీలు, మైనార్టీలపై

దమనకాండ ఆపాలి

శాంతిని నెలకొల్పేందుకు చర్యలు తీసుకోవాలి

- సోయం బాపూరావు వ్యాఖ్యలు సరికావు
తెలంగాణలో బీజేపీ మెజారిటీయన్ సిద్ధాంతాన్ని తిప్పికొడతాం : ప్రజా సంఘాల రౌండ్ టేబుల్ సమావేశంలో నాయకులు



అవాజ్ ప్రధాన కార్యదర్శి మహమ్మద్ అబ్దుల్ మజిదులూ మైనార్టీలూ రాజ్యాంగంలోని ఐదవ షెడ్యూల్ ప్రకారం ఎన్నో జాతితాల్ చేర్చేందుకు రాజ్యాంగ సవరణ చేయాలి...

సంక్షేమ సంఘం రాష్ట్ర కార్యదర్శి రఘు మజిదులూ మైనార్టీలపై మతేన్యూర దాడులను తిప్పికొట్టేందుకు సంఘటితం కావాలని పిలుపునిచ్చారు.

అవాజ్ ప్రధాన కార్యదర్శి మహమ్మద్ అబ్దుల్ మజిదులూ మైనార్టీలూ రాజ్యాంగంలోని ఐదవ షెడ్యూల్ ప్రకారం ఎన్నో జాతితాల్ చేర్చేందుకు రాజ్యాంగ సవరణ చేయాలి...

సంక్షేమ సంఘం రాష్ట్ర కార్యదర్శి రఘు మజిదులూ మైనార్టీలపై మతేన్యూర దాడులను తిప్పికొట్టేందుకు సంఘటితం కావాలని పిలుపునిచ్చారు.

CONCORD DRUGS LIMITED financial statement table with columns for Quarter Ended, Year to Date, and Corresponding 3 months.

VISTA PHARMACEUTICALS LTD financial statement table with columns for Quarter Ended, Year to Date, and Corresponding 3 months.

For Vista Pharmaceuticals Ltd
Director: Divakar Reddy Yerrabommahalli
DIN: 0.08574891

పదవి నుంచి తప్పించాలి

అరెస్టు చేసి కఠినంగా శిక్షించాలి : టీఎస్ యూటీఎఫ్ డిమాండ్

రెజిస్టర్ పోరాటానికి మద్దతుగా రాల్చి
సవతెలంగాణ-సీటీబిఎల్లో భారత రెజిస్ట్రేషన్ లైంగిక వేధింపులకు పాల్పడిన భారత రెజిస్ట్రేషన్ ఫెడరేషన్ అధ్యక్షుడు, బీజేపీ ఎంపీ బ్రిజ్ భూషణ్ శర్మ సింగ్ ను పదవి నుంచి తొలగించాలని టీఎస్ యూటీఎఫ్ రాష్ట్ర అధ్యక్షులు కె.జె.అగయ్య డిమాండ్ చేశారు.



పోనంగా ఉండటం సరైనది కాదన్నారు. ఈ కార్యక్రమంలో టీఎస్ యూటీఎఫ్ రాష్ట్ర ప్రధాన కార్యదర్శి చావ రవి, కోశాధికారి లక్ష్మారెడ్డి, కార్యదర్శులు సోమేశ్వర్, వెంకట్, రాజశేఖర్ రెడ్డి, శాంతకుమారి, నాగమణి, రవికుమార్, శ్రీధర్, సింహపలం, జ్ఞాన మంజరి, మహబూబ్ అలీ, కొండరావు, పలువురు రాష్ట్ర కమిటీ సభ్యులు, వివిధ జిల్లాల అధ్యక్ష కార్యదర్శులు పాల్గొన్నారు.

VARIMAN GLOBAL ENTERPRISES LIMITED

VARIMAN GLOBAL ENTERPRISES LIMITED financial statement table with columns for Quarter Ended, Year to Date, and Corresponding 3 months.

VIVO BIO TECH LIMITED

VIVO BIO TECH LIMITED financial statement table with columns for Quarter Ended, Year to Date, and Corresponding 3 months.

రెజిస్ట్రేషన్ ప్రభుత్వంపై ప్రసవాలు

సవతెలంగాణ టీఎస్ యూటీఎఫ్ ప్రసవాలు రెజిస్ట్రేషన్ యూనిట్ వైద్యారోగ్యశాఖ మంత్రి హరీష్ రావు తెలిపారు. ఈ మేరకు బుధవారం ఆయన ట్వీట్ చేశారు. దీంతో ప్రభుత్వంపై ప్రసవాల విషయంలో తెలంగాణ రికార్డ్ సృష్టించినట్లు చెప్పారు.

RESPONSE INFORMATICS LIMITED

RESPONSE INFORMATICS LIMITED financial statement table with columns for Quarter Ended, Year to Date, and Corresponding 3 months.